NEVVI Medicare utilization intelligence
+ Build a code basket
Market snapshot

Nationwide CY2024

Medicare Part B FFS · CY2024 · as published by CMS
87427 Detection test by immunoassay technique for shiga-like toxin (bacterial toxin) CPT · General Laboratory test
Classification Test General Laboratory Immunoassay (CMS RBCS)
First observed 2013 — start of our 12-year window; the code predates it
National scale 178,815 services · est. ▲ 3.3% YoY · 82,515 FFS beneficiaries (CY2024, all-Medicare estimate) — 87,092 observed fee-for-service services
CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window
Data year: CY2024 CY2023 CY2022 locked column CY2021 locked column CY2020 locked column
Market overview
Market Brief 87427
The whole of 87427, written up and sourced.

The Brief is a national document for 87427. Its findings page carries one finding per chapter, each opening the chapter that prints its figure and the table behind it — like these, from the United States, CY2024, the market on this page.

  1. 1Size and growth. The national market for 87427 ran ~178,815 all-Medicare services (estimated), 87,092 observed fee-for-service in CY2024. The market is up 3.3% year over year. 1 billing group and 6 clinicians bill it.
  2. 2Geography. NC, NJ, FL and AZ lead the state markets — together 46% of state-market volume.
Estimated all-Medicare volume estimate
FFS + estimated MA

~178,815 services

87,092 observed fee-for-service (49%) · ~91,723 estimated Medicare Advantage.

Scaled from the observed floor by each state’s fee-for-service share (FFS share as of 2024) — scaled estimate — assumes MA utilization mirrors FFS; not an observation. How we scale
Average charge

$100-3.9% vs 2023

per service, submitted list amounts — not payments · named-group basis, observed FFS
Average payment

$12flat vs 2023

per service, Medicare paid amounts — not charges · all disclosed claims, observed FFS basis
Charge-to-payment ratio

8.5×-3.9% vs 2023

average list $100 vs average Medicare payment $12 per service · named-group basis
Where the market isobserved FFS services by state · CY2024
MEVTNHWA: 3361WAIDMTND: 144NDMNWI: 1169WIIL: 1978ILMI: 150MINY: 133NYMA: 2581MARIOR: 310ORNV: 458NVWY: 17WYSD: 75SDIA: 247IAINOH: 3476OHPA: 726PANJ: 11041NJCT: 37CTCA: 7821CAUT: 18UTCO: 333CONE: 72NEMO: 2512MOKY: 407KYWVVA: 1133VAMD: 885MDDE: 12DEAZ: 8693AZNMKS: 154KSAR: 272ARTN: 1252TNNC: 11060NCSCDCOK: 803OKLA: 615LAMS: 215MSAL: 4656ALGA: 2143GAHI: 606HIAKTX: 7888TXFL: 9627FL
Shaded low→high on observed fee-for-service services billed from each state · the /stats tile grid, at national scope. Shading ranks the states rather than spacing them along the range, so neighbouring shades mean adjacent RANKS, not equal gaps — the key names the lowest and highest; each tile carries its own figure.
Which states movedservices per 1,000 FFS beneficiaries · CY2021 → CY2024
CY2021CY2024AL: 9 → 12AR: 0 → 1CA: 5 → 3CO: 1 → 1GA: 2 → 3HI: 2 → 6IA: 1 → 1IL: 1 → 2KS: 1 → 0KY: 1 → 1LA: 1 → 2MA: 5 → 3MD: 1 → 1MI: 0 → 0MO: 4 → 5MS: 0 → 1ND: 1 → 2NE: 0 → 0NV: 2 → 2NY: 0 → 0OH: 4 → 4OK: 2 → 2OR: 2 → 1PA: 1 → 1SD: 0 → 1TN: 2 → 2TX: 5 → 4UT: 0 → 0VA: 0 → 1WA: 5 → 5WI: 2 → 2WY: 0 → 0AZ: 8 → 14FL: 6 → 5NC: 12 → 13NJ: 11 → 13NC 12NJ 11AZ 8FL 614 AZ13 NC13 NJ5 FL
One line per state market, 36 drawn; the 4 leading states by volume are in accent, the rest are context lines. Both columns share one scale, so a slope is real change. A RATE against each state’s own fee-for-service population — assumption-free, and no all-Medicare estimate is used or implied. CY2021 is the left period because CY2020 is the pandemic year and a slope off it would read as growth almost everywhere. 8 states with a rate in only one of the two years are not drawn.

Open a state market: NC · NJ · FL · AZ · TX · CA · AL · OH · WA · MA · MO · GA — the group ranking lives in the Provider groups tab. Territories bill too; the tile grid draws the 50 states and DC.